Arena Pharmaceuticals Inc. (ARNA)

46.40
NASDAQ : Health Technology
Prev Close 46.40
Day Low/High 0.00 / 0.00
52 Wk Low/High 12.20 / 47.64
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 49.23M
Market Cap 2.28B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Small-Caps Are the Place to Be for Now

Small-Caps Are the Place to Be for Now

We are seeing a focus on finding smaller names that may offer interesting valuations and stories.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

Reminder: Healthy Stock Markets Decline, Too

Reminder: Healthy Stock Markets Decline, Too

The key for the overall market now is that it hold above today's early lows.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Sector charts should shape up as worries about prices are finally put to rest.

Having Some Good Luck With Biotech Names

Having Some Good Luck With Biotech Names

Overall it is still a positive day but the action is sloppy.

Markets Make an Art of Unpredictability

Markets Make an Art of Unpredictability

Oil isn't the only reason stocks are higher.

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

Smaller Companies Are Often Some of the Best Trading Vehicles

Smaller Companies Are Often Some of the Best Trading Vehicles

The challenge of this market is that the upward moves have not been well sustained.

Arena Pharmaceuticals And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound

- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

It's not all about the bond market, says Jim Cramer. The central issues here are trade, tariffs and most important, the stocks themselves, like Facebook and Amazon.

ARNA June 8th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 8th contracts and identified one put and one call contract of particular interest.

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

Rotational action is the main theme Wednesday and good opportunities are out there.

ARNA May 11th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 11th contracts and identified one put and one call contract of particular interest.

My Biggest Concern About This Stock Market

My Biggest Concern About This Stock Market

There's a worrisome scenario that could develop this afternoon.

Here's When You Can Buy Twitter's Stock

Here's When You Can Buy Twitter's Stock

There just aren't any pockets of strong momentum right now.

Arena Pharmaceuticals Reports Positive Phase 2 Results From The OASIS Trial For Etrasimod In Patients With Ulcerative Colitis

Arena Pharmaceuticals Reports Positive Phase 2 Results From The OASIS Trial For Etrasimod In Patients With Ulcerative Colitis

- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks

TheStreet Quant Rating: D (Sell)